BioSpace News Archive

AIM ImmunoTech, announced that it will be presenting at The LD 500 Investor conference being held virtually on September 1-4, 2020.

MediWound Ltd. and its U.S. commercial partner Vericel Corporation announced that the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has accepted the first shipment of NexoBrid® as part of its mission to build national preparedness for public health emergencies.

Board of Directors Appoints Dane C. Andreeff as Interim President and Chief Executive Officer and Appoints Blane Walter as Chairman of the Board of Directors

Primary endpoint achieved, demonstrating a statistically significant reduction of seizures from baseline compared to placebo (p=0.0007) in the combined Dravet syndrome and Lennox-Gastaut syndrome study population

Use of MammaPrint genetic assay alongside clinical assessment is cost-effective versus clinical assessment alone

TSMC grows partnership with Ansys to provide advanced power integrity and electromigration signoff tools for next-generation applications

Gerald Moeller, Ph.D., Elected Chairman of Supervisory Board; Rainer Strohmenger, MD, and Shinichiro Fuse, Ph.D., Named Supervisory Board Members

Sirnaomics, Inc. announced that it has published data from a preclinical discovery effort using a novel siRNA-gemcitabine conjugate construct to enhance therapeutic efficacy of the active pharmaceutical ingredient potentially for treatment of multiple types of cancer.

BeiGene, Ltd., a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, announced the appointment of Corsee Sanders, Ph.D. to its Board of Directors and to the Audit and Scientific Advisory Committees of the Board.

Bristol Myers Squibb announced that the Phase 3 IDHENTIFY study evaluating IDHIFA® plus best supportive care versus conventional care regimens, which include best supportive care only, azacitidine plus BSC, low-dose cytarabine plus BSC or intermediate-dose cytarabine plus BSC, did not meet the primary endpoint of overall survival in patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation.